COMPOSITION: Each LuciLenva capsule contains: 12.25mg Lenvatinib mesylate equivalent to Lenvatinib.………10mg INDICATION: LuciLenva is a kinase inhibitor that is indicated: 1. For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 2. In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC). 3. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). DOSAGE AND USE: 1. DTC: The recommended dosage is 24 mg orally once daily. 2. RCC: The recommended dosage is 18 mg orally with everolimus 5 mg orally once daily. 3. HCC: The recommended dosage is based on actual body weight: · 12 mg orally once daily for patients greater than or equal to 60 kg · 8 mg orally once daily for patients less than 60 kg. Capsules should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each LuciLenva capsule contains: 12.25mg Lenvatinib mesylate equivalent to Lenvatinib.………4mg INDICATION: LuciLenva is a kinase inhibitor that is indicated: 1. For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 2. In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC). 3. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). DOSAGE AND USE: 1. DTC: The recommended dosage is 24 mg orally once daily. 2. RCC: The recommended dosage is 18 mg orally with everolimus 5 mg orally once daily. 3. HCC: The recommended dosage is based on actual body weight: · 12 mg orally once daily for patients greater than or equal to 60 kg · 8 mg orally once daily for patients less than 60 kg. Capsules should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each LuciTivo capsule contains Tivozanib hydrochloride 1mg equivalent to Tivozanib…………………… 1.34mg. INDICATION: LuciTivo is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. DOSAGE AND USE: • Recommended Dose: 1.34 mg once daily with or without food for 21 days on treatment followed by 7 days off treatment (28-day cycle) until disease progression or unacceptable toxicity. • Dose interruptions and/or dose reduction may be needed to manage adverse reactions. • For patients with moderate hepatic impairment, reduce the dose to 0.89 mg for 21 days on treatment followed by 7 days off treatment (28-day cycle). STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each LuciTivo capsule contains Tivozanib hydrochloride 1mg equivalent to Tivozanib……………………. 0.89mg. INDICATION: LuciTivo is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. DOSAGE AND USE: • Recommended Dose: 1.34 mg once daily with or without food for 21 days on treatment followed by 7 days off treatment (28-day cycle) until disease progression or unacceptable toxicity. • Dose interruptions and/or dose reduction may be needed to manage adverse reactions. • For patients with moderate hepatic impairment, reduce the dose to 0.89 mg for 21 days on treatment followed by 7 days off treatment (28-day cycle). STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each film-coated tablet contains Erdafitinib …………5 mg INDICATION: LuciErda is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has • susceptible FGFR3 or FGFR2 genetic alterations and • progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. DOSAGE AND USE: • Confirm the presence of FGFR genetic alterations in tumor specimens prior to initiation of treatment with LuciErda. • Recommended initial dosage: 8 mg orally once daily with a dose increase to 9 mg daily if criteria are met. • Swallow whole with or without food. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each film-coated tablet contains Erdafitinib …………4 mg INDICATION: LuciErda is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has • susceptible FGFR3 or FGFR2 genetic alterations and • progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. DOSAGE AND USE: • Confirm the presence of FGFR genetic alterations in tumor specimens prior to initiation of treatment with LuciErda. • Recommended initial dosage: 8 mg orally once daily with a dose increase to 9 mg daily if criteria are met. • Swallow whole with or without food. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each film-coated tablet contains Erdafitinib …………3 mg INDICATION: LuciErda is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has • susceptible FGFR3 or FGFR2 genetic alterations and • progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. DOSAGE AND USE: • Confirm the presence of FGFR genetic alterations in tumor specimens prior to initiation of treatment with LuciErda. • Recommended initial dosage: 8 mg orally once daily with a dose increase to 9 mg daily if criteria are met. • Swallow whole with or without food. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each tablet contains Mitotane……………500 mg INDICATION: LUCIMITO is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenal cortical carcinoma. DOSAGE AND USE: The recommended initial dose of LUCIMITO is 2 g to 6 g orally, in three or four divided doses per day. Increase doses incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated. LUCIMITO is a cytotoxic drug. Follow applicable special handling and disposal procedures. Tablets should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

COMPOSITION: Each LuciCyp tablet contains:50 mg cyproterone acetate. INDICATION: 1.Indications in females Severe signs of androgenisation, e.g. very severe hirsutism, androgen-dependent severe loss of scalp hair eventually resulting in baldness (severe androgenic alopecia), often attended by severe forms of acne and/ or seborrhoea. 2.Indications in males Reduction of drives in sexual deviations. Anti-androgen treatment in inoperable carcinoma of the prostate. DOSAGE AND USE: The usual dose is 1 tablet twice a day. Once the desired effect is achieved, your dose may be gradually lowered. Take the tablet after your morning and evening meals. The maximum daily dose is 300 mg. STORAGE: Store at or below 30°C and in a dry place. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos